Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar: financing pressure. About 10.0 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), an at-the-market (ATM) program filed Mar 16, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$30.9MCash on Hand
10mo Cash Runway
Follow ELTX by emailGet an email when ELTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ELTX, unsubscribe in one click. Privacy
📣 What ELTX Says Is Next
Q4 2026 · “Elicio is targeting a Q4 2026 initiation of a Phase 1 study evaluating camupepimut with daraxonrasib, with or without nivolumab, in metastatic KRAS-mutated PDAC.”
Company press release, Nov 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Shareholder vote Shareholders at the Nov 12, 2026 annual meeting re-elected Julian Adams, Ph.D., Jay R. Venkatesan, M.D., and Carol Ashe as Class III directors, and ratified Baker Tilly US, LLP as auditor for fiscal 2026. Each proposal passed. Form 8-K · SEC filing
Nov 5, 2026 ·
Earnings Reported Q3 2026 results: net loss of $8.0 million ($0.30 per share) versus $10.1 million a year earlier, with $30.9 million in cash expected to fund operations into Q2 2027. Also highlighted Phase 2 AMPLIFY-7P data in adjuvant PDAC. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 9, 2026 ·
Shareholder vote Annual meeting set for November 12, 2026, held virtually. Stockholders will elect three Board nominees, Julian Adams, Ph.D., Jay Venkatesan, M.D. and Carol Ashe, and ratify Baker Tilly US, LLP as independent auditor for fiscal 2026. Form DEF 14A · SEC filing
Sep 14, 2026 ·
Shareholder vote Elicio Therapeutics set November 12, 2026 as the date of its 2026 annual stockholder meeting. Stockholder proposals under Rule 14a-8 and director nominations must be received by September 24, 2026. Form 8-K · SEC filing
Aug 13, 2026 ·
Earnings Reported Q2 2026 net loss of $8.2 million ($0.43 per share) and cash of $23.5 million, with runway into Q1 2027. Phase 2 AMPLIFY-7P missed its primary endpoint; a $15.0 million registered direct offering closed in July 2026. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2026 · Phase 1/2 · Active Trial · A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors Registry primary completion date, not a results date
Jan 2023 · Phase 1 · Results Expected · A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not ELTX's own candidates): Tislelizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ELTX holds $30.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $9.3M/quarter from operations,
an estimated runway of 10 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:90 · High
Cash runway 10 months +30
ATM program on file since Mar 2026 +15
Shelf registration (S-3, Feb 2026) +10
Going-concern doubt in the latest 10-Q +15The Company’s losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the condensed consolidated financial statements, raise substantial doubt about the Company’s ability to continue…10-Q, Nov 2026
Share count 28,307,225 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ELTX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ELTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.